retatrutide triple agonist obesity trial π¨ TRIUMPH-1 Phase 3 top-line results, much awaited and just announced β¬οΈ 28.3% Weight loss at 80 weeks β¬οΈ 30.3% weight loss at 104 weeks among adults with baseline BMI >35 retatrutide triple agonist gip glp-1
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Sep 5 - Sep 10



























